Results

1–10 of 10 results for Peter K. Kaiser

Use of Ellipsoid Zone Analysis As an Efficacy Endpoint in Clinical Trials for Geographic Atrophy
Peter K. Kaiser, MD FASRS
Annual Meeting Talks
2023
Multicenter Randomized Sham-Controlled Double-Masked Phase 2b Clinical Trial of Multi-Characteristic Opsin in Patients With Advanced Retinitis Pigmentosa
Peter K. Kaiser, MD FASRS
Annual Meeting Talks
2022
Avacincaptad Pegol, A Novel C5 Inhibitor, and GATHER1 Study: Results From a Post-Hoc Analysis of Nascent Geographic Atrophy
Peter K. Kaiser, MD FASRS
Annual Meeting Talks
2021
Clinical Evaluation and PK/PD Modeling of the DARPin Therapeutic Abicipar for the Treatment of Neovascular Age‐Related Macular Degeneration
Peter K. Kaiser, MD FASRS
Annual Meeting Talks
2020
TIE2, VEGF, and Integrin Receptor Interplay and its Role in Retinal Disease
Peter K. Kaiser, MD FASRS
Updates from the Field
2020
Safety and Efficacy of Risuteganib in Intermediate Nonexudative AMD: First Time Results From a Phase 2 Study
Peter K. Kaiser, MD FASRS
Annual Meeting Talks
2019
AMD Neovascular Expert Panel
Robert L. Avery, MD
Nizar S Abdelfattah, M.D.
Nancy M. Holekamp, MD, FASRS
Peter K. Kaiser, MD FASRS
Pravin U. Dugel, MD
Annual Meeting Talks
2016
Complications or Are They: Why We Can NEVER Get Enough ReST
Jeffrey S. Heier, MD
Peter K. Kaiser, MD FASRS
Geoffrey G. Emerson, MD, PhD, FASRS
J. Michael Jumper, MD, FASRS
Ehab N. ELRAYES, MD, PhD ,FASRS
Daniel Simhaee, MD
ASSAF DOTAN, MD
Paul Hahn, MD, PhD, FASRS
Philip J. Ferrone, MD, FASRS
Annual Meeting Talks
2018
Randomized, Prospective, Double-Masked, Controlled Phase 2b Trial to Evaluate the Safety and Efficacy of ALG-1001 (Luminate®) in Diabetic Macular Edema
Peter K. Kaiser, MD FASRS
Annual Meeting Talks
2018
Therapies for Diabetic Macular Edema: What’s in the Pipeline?
Peter K. Kaiser, MD FASRS
Updates from the Field
2018